Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke. Stroke. 2019;50:3331 2. 169. Professional Practice Committee. Professional Practice Committee: Standards of medical care in dia- betes-2020. Diabetes Care. 2020;43 Suppl 1:S3. 170. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095 105. 171. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497 506. 172. Mancia G, Rea F, Ludergnani M, et al. Renin- angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431 40. 173. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin- angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441 8. 174. Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Car- diol. 2020;5:1020 6. 175. de Abajo FJ, Rodriguez-Martin S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705 14. 176. BRACE CORONA: does temporarily suspending RAAS inhibitors show clinical bene t in hospitalized COVID-19 patients? ACC News Story. Published September 1, 2020. Available at: https://www.acc.org/ ace-inhibitors-arbs-esc-2020. Accessed October 10, 2020. KEY WORDS ACC Expert Consensus Decision Pathway, ARNI, heart failure, HFrEF, SGLT2 inhibitor Maddox et al. 